Article Data

  • Views 863
  • Dowloads 160

Original Research

Open Access

Luteoloside inhibiting the prostate cancer cells growth and promoting the tumor cells autophagy through AKT/mTOR pathway

  • Haoyue Li1
  • Xi Wang1
  • Aiyangzi Lu1
  • Yongmei Pan2
  • Wei Zhang3
  • Lei Hao1,*,

1Department of Clinical Chinese Medicine, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China

2Huang Di Neijing Teaching and Research Office, Hebei University of Chinese Medicine, 050200 Shijiazhuang, Hebei, China

3Department of Pharmacy, Hebei Hospital of Traditional Chinese Medicine, 050000 Shijiazhuang, Hebei, China

DOI: 10.22514/jomh.2023.047 Vol.19,Issue 6,June 2023 pp.49-55

Submitted: 06 April 2023 Accepted: 08 June 2023

Published: 30 June 2023

*Corresponding Author(s): Lei Hao E-mail: haolei0706@163.com

Abstract

Prostate cancer (PC) is one of the prevalent tumors in men causing higher mortality. Luteoloside has been discovered for suppressive role into the progression of some cancers. However, the Luteoloside’s regulatory functions regarding PC progression are not well understood. This study is thus designed to investigate the Luteoloside impact on PC progression. In this work, it was demonstrated that the PC cell proliferation was gradually inhibited with the increasing Luteoloside dose (0, 20, 40, 80 µM). Luteoloside also enhanced the PC cell apoptosis. It promoted the autophagy in PC through increasing microtubule-associated protein light chain (LC) 3II/LC3I levels and decreasing p62 levels. Moreover, the Luteoloside reduced phosphorylated-protein kinase B (p-AKT)/AKT and phosphorylated-mechanistic target of rapamycin (p-mTOR)/mTOR levels, indicating that it retarded the AKT/mTOR pathway. In conclusion, the Luteoloside inhibited PC cells growth and promoted tumor cells autophagy through AKT/mTOR pathway. This discovery suggested the Luteoloside as a potential drug in treating PC.


Keywords

Luteoloside; Autophagy; Prostate cancer; AKT/mTOR pathway


Cite and Share

Haoyue Li,Xi Wang,Aiyangzi Lu,Yongmei Pan,Wei Zhang,Lei Hao. Luteoloside inhibiting the prostate cancer cells growth and promoting the tumor cells autophagy through AKT/mTOR pathway. Journal of Men's Health. 2023. 19(6);49-55.

References

[1] Nguyen-Nielsen M, Borre M. Diagnostic and therapeutic strategies for prostate cancer. Seminars in Nuclear Medicine. 2016; 46: 484–490.

[2] Murphy GP. Management of metastatic prostatic cancer. Progress in Clinical and Biological Research. 1988; 277: 127–134.

[3] Litwin MS, Tan H. The diagnosis and treatment of prostate cancer. JAMA. 2017; 317: 2532–2542.

[4] Kullmann T. Complementary elements to the pathogenesis, early detection and second line antihormonal therapy of prostate cancer. Journal of Men’s Health. 2022; 18: 155.

[5] Caporali S, De Stefano A, Calabrese C, Giovannelli A, Pieri M, Savini I, et al. Anti-inflammatory and active biological properties of the plant-derived bioactive compounds luteolin and luteolin 7-glucoside. Nutrients. 2022; 14: 1155.

[6] Shao J, Wang C, Li L, Liang H, Dai J, Ling X, et al. Luteoloside inhibits proliferation and promotes intrinsic and extrinsic pathway-mediated apoptosis involving MAPK and mTOR signaling pathways in human cervical cancer cells. International Journal of Molecular Sciences. 2018; 19: 1664.

[7] Ji J, Wang Z, Sun W, Li Z, Cai H, Zhao E, Cui H, et al. Effects of cynaroside on cell proliferation, apoptosis, migration and invasion though the MET/AKT/mTOR axis in gastric cancer. International Journal of Molecular Sciences. 2021; 22: 12125.

[8] Zhou M, Shen S, Zhao X, Gong X. Luteoloside induces G0/G1 arrest and pro-death autophagy through the ROS-mediated AKT/mTOR/p70S6K signalling pathway in human non-small cell lung cancer cell lines. Biochemical and Biophysical Research Communications. 2017; 494: 263–269.

[9] Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, et al. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLOS ONE. 2014; 9: e89961.

[10] Huang H, Wang Q, Du T, Lin C, Lai Y, Zhu D, et al. Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B. The Prostate. 2018; 78: 327–335.

[11] Meng F, Yang J, Yang C, Jiang Y, Zhou Y, Yu B, et al. Vitexicarpin induces apoptosis in human prostate carcinoma PC-3 cells through G2/M phase arrest. Asian Pacific Journal of Cancer Prevention. 2012; 13: 6369–6374.

[12] Liang B, Cui S, Zou S. Leonurine suppresses prostate cancer growth in vitro and in vivo by regulating miR-18a-5p/SLC40a1 axis. Chinese Journal of Physiology. 2022; 65: 319–327.

[13] Tamgue O, Lei M. Triptolide promotes senescence of prostate cancer cells through histone methylation and heterochromatin formation. Asian Pacific Journal of Cancer Prevention. 2017; 18: 2519–2526.

[14] Ma X, Ren H, Zhang Y, Wang B, Ma H. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway. Environmental Toxicology. 2022; 37: 3013–3027.

[15] Cai F, Li J, Zhang J, Huang S. Knockdown of circ_CCNB2 sensitizes prostate cancer to radiation through repressing autophagy by the miR-30b-5p/KIF18a axis. Cancer Biotherapy and Radiopharmaceuticals. 2022; 37: 480–493.

[16] Nam RK, Benatar T, Amemiya Y, Sherman C, Seth A. Mir-139 regulates autophagy in prostate cancer cells through beclin-1 and mTOR signaling proteins. Anticancer Research. 2020; 40: 6649–6663.

[17] Yu Y, Song Y, Cheng L, Chen L, Liu B, Lu D, et al. CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells. Journal of Experimental & Clinical Cancer Research. 2022; 41: 188.

[18] Ding M, Jiang C, Zhang Y, Zhao J, Han B, Xia S. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer. Journal of Experimental & Clinical Cancer Research. 2020; 39: 28.

[19] Cristofani R, Montagnani Marelli M, Cicardi ME, Fontana F, Marzagalli M, Limonta P, et al. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells. Cell Death & Disease. 2018; 9: 889.

[20] Lee EH, Lee JN, Park S, Chun SY, Yoon BH, Chung J, et al. Inhibition of TRPM7 suppresses migration and invasion of prostate cancer cells via inactivation of ERK1/2, Src and Akt pathway signaling. Journal of Men’s Health. 2022; 18: 144.

[21] Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. International Journal of Molecular Sciences. 2020; 21: 4507.

[22] Qiu J, Zhang Y, Xie M. Chrysotoxine attenuates sevoflurane-induced neurotoxicity in vitro via regulating PI3K/AKT/GSK pathway. Signa Vitae. 2021; 17: 185–191.

[23] Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Frontiers in Oncology. 2022; 12: 819128.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top